It is a well known fact that Microsoft Corporation MSFT co-founder Bill Gates, through his Bill & Melinda Gates Foundation, works to eliminate infectious diseases and eradicate poverty in developing and underdeveloped countries.
Gates took to Twitter this week to share details of another illness he is working on.
“We are announcing the second phase of @TheADDF’s diagnostics accelerator,” he said.
“I hope this new phase will make progress that will help change the course of Alzheimer’s disease.”
We announce the second phase of @ADDFdiagnostic accelerator. I am hopeful that this new phase will make progress that will help change the course of Alzheimer’s disease. https://t.co/VwsdNDsBDf
— Bill Gates (@BillGates) July 28, 2022
The Alzheimer’s Drug Discovery Foundation (ADDF) launched the “Diagnostics Accelerator” in 2018, with inaugural funding from Gates, Estee Lauder Companies Inc. EL Leonard Lauder, Amazon, Inc. AMZN founder Jeff Bezos and the Dolby family. The project plans to make Alzheimer’s tests affordable, as those that exist are expensive and invasive.
Related Link: The Alzheimer’s Drug Pipeline: High Failure Rates in Research into an Increasingly Common Disease
“The goal is to develop reliable and affordable biomarker tests, just as cholesterol is considered an early biomarker of heart disease risk,” the ADDF said on its website.
All of these are essential for developing effective preventive and curative treatments for Alzheimer’s disease, he added. Diagnostics Accelerator has now received an additional $50 million in financial commitments from new backers, including the NFL Players Association, Eli Lilly & Company THERE IS, Biogene, Inc. IBIB and the Shanahan Family Foundation. This brings the total funding received since 2018 to $100 million.
Effective treatments for Alzheimer’s disease, a neurological disorder, have so far eluded researchers due to the difficulty in diagnosing the disease at an early stage and delivering the drug to the brain for testing.
Biogen had a very difficult launch for its controversial Alzheimer’s drug Aduhelm, with CMS offering very limited coverage for this expensive treatment.
Photo: Courtesy of the National Museum of American History Smithsonian Institution and OnInnovation on flickr